Fosamax and Osteonecrosis of the Jaw: Understanding the FDA Warning and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

The legacy of general health and science information has long served as a foundational resource for public awareness, emphasizing broad preventive measures and lifestyle factors. This heritage, rooted in accessible communication of medical knowledge, has historically focused on common conditions and widely applicable health guidance. As industrial processes evolve, however, the scope of health information must adapt to address specific risks emerging from occupational and environmental exposures. The transition from general health contexts to targeted concerns involves recognizing how certain materials and compounds used in manufacturing can intersect with individual health outcomes. For instance, the widespread use of bisphosphonates like Fosamax in treating osteoporosis represents a medical intervention that, while beneficial for many, has prompted regulatory scrutiny regarding rare but serious adverse events. The FDA warning linking Fosamax to osteonecrosis of the jaw highlights a critical juncture where pharmaceutical exposure becomes a relevant consideration for workers in production settings. This pivot underscores the need to examine how occupational exposure to such substances—whether through direct handling, environmental contamination, or secondary contact—may elevate risk profiles beyond typical patient populations. By bridging from general health literacy to specific exposure scenarios, the focus shifts toward identifying and mitigating hazards inherent in mass production environments, ensuring that health information remains responsive to the complexities of modern industrial practice.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence and FDA Warnings

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by bone death in the jaw that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The U.S. Food and Drug Administration (FDA) has issued warnings regarding this adverse effect, which are included in the drug's prescribing information. The clinical presentation of ONJ involves exposed necrotic bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with biopsy sometimes used to rule out other conditions. The condition can be debilitating, requiring surgical intervention and long-term management. The FDA warning notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Risk Assessment for Fosamax-Related ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This suppression can impair the jawbone's ability to repair microdamage and respond to local infections or trauma, particularly in areas of high mechanical stress such as the jaw. Multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's unique structure and high remodeling rate may make it particularly vulnerable to the effects of bisphosphonate accumulation. Regarding the adequacy of warnings, the FDA label for Fosamax includes a specific section on ONJ under "Warnings and Precautions" (5.4). The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may suggest that the absolute risk is low in the general population but can be higher in those with additional risk factors. Causation considerations for affected patients are complex. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients have relief of symptoms after stopping the drug, but a subset may experience recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some individuals. The introduction of equivalent dose (ED) and threshold dose (TD) metrics has been proposed as predictive risk assessment tools for medication-related ONJ, with ED standardized to the cumulative dose of four years of weekly oral alendronate use (14,560 mg) (https://pubmed.ncbi.nlm.nih.gov/40619534/). This suggests that cumulative exposure is a key factor in risk assessment. The timeline between exposure and documented harm can be variable. ONJ may develop after months to years of bisphosphonate use, and the risk increases with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients at low risk for fracture, the label recommends considering drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may help reduce the risk of ONJ. However, the optimal duration of use has not been determined (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the evidence supports a causal association between Fosamax and ONJ, particularly in patients with additional risk factors. The FDA warnings are present but may not fully convey the variable risk based on individual patient factors and cumulative dose. Affected patients should be evaluated for risk factors and considered for dental evaluation before initiating bisphosphonate therapy. Discontinuation of treatment may reduce risk for those requiring invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning regarding Fosamax and osteonecrosis of the jaw?

The FDA has issued warnings that Fosamax (alendronate) is associated with osteonecrosis of the jaw (ONJ), a condition of bone death in the jaw. The warning is included in the drug's prescribing information under 'Warnings and Precautions' (5.4), noting that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How is Fosamax-related ONJ diagnosed and treated?

Diagnosis is based on clinical examination and imaging, with biopsy sometimes used to rule out other conditions. Treatment involves surgical intervention and long-term management. Discontinuation of bisphosphonate treatment may reduce the risk for those requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.